Bio News
Kodiak Sciences said its eye disease treatment Zenkuda demonstrated noninferiority to Eylea with dosing intervals of up to 6 months.
Kodiak cited a tool that identifies patients who need more frequent injections based on fluid levels in the eye as a key factor in the success.
Based on these data, Kodiak plans to apply for approval from the U.S. Food and Drug Administration (FDA) by the end of the year.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
